Last reviewed · How we verify

NCT06856447

The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer

Recruiting now Phase 1 Last updated 4 March 2025
What this trial tests

Phase 1 trial testing Coenzyme Q10 in Colorectal Cancer in 22 participants. Currently enrolling.

Timeline
1 June 2024
Primary endpoint
20 May 2025
10 January 2026

Quick facts

Lead sponsortoqa saad mohammed mohammed
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment22
Start date1 June 2024
Primary completion20 May 2025
Estimated completion10 January 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

toqa saad mohammed mohammed — full company profile →

Who can join

18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the possible beneficial role of coenzyme Q10 against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Coenzyme Q10

Trials testing the same drug.

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06856447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing